Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies

933MO - Longitudinal monitoring of circulating tumor DNA from plasma in patients with curative resected stage IA-IIIA EGFR mutant non-small cell lung cancer


12 Sep 2022


Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies


Molecular Oncology

Tumour Site

Non-Small Cell Lung Cancer


Myung-Ju Ahn


Annals of Oncology (2022) 33 (suppl_7): S427-S437. 10.1016/annonc/annonc1062


M. Ahn1, H.A. Jung1, B.M. Ku2, Y.J. Kim3, S. Park1, J. Sun1, S. Lee1, J.S. Ahn1, J.H. Cho4, H.K. Kim4, Y.S. Choi4, J. Kim4

Author affiliations

  • 1 Division Of Hematology And Oncology, Department Of Medicine, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 2 Research Institute For Future Medicine, Samsung Medical Center (SMC), 06351 - Seoul/KR
  • 3 Samsung Genomic Institute, Samsung Medical Center (SMC), 06351 - Seoul/KR
  • 4 Department Of Thoracic Surgery, Samsung Medical Center (SMC), 06351 - Seoul/KR


Login to access the resources on OncologyPRO.

Abstract 933MO


For patients with early stage epidermal growth factor receptor mutation positive (EGFR-M+) non-small cell lung cancer (NSCLC), curative surgery followed by adjuvant chemotherapy is considered the standard of care. Recently, based on the ADAURA study, osimertinib was approved in resected stage IB-IIIA EGFR-M+ NSCLC. The circulating tumor DNA (ctDNA) provides a potential biomarker for detection of minimal residual disease (MRD) and recurrence. We investigated the longitudinal monitoring of ctDNA test in early stage EGFR-M+ NSCLC.


Between August 2015 and October 2017, 278 patients with curative resected, stage IA-IIIA EGFR-M+ NSCLC were enrolled. Radiological follow-up was accompanied with longitudinal monitoring of ctDNA using a droplet digital PCR from baseline and follow-up per protocol until 5 years or recurrence.


Median follow-up duration was 62.0 months (range, 1.5-774). Among 278 patients, stage IA, IB, IIA, IIB, and IIIA comprised 60.1%, 18.3%, 10.1%, 2.2%, and 9.4%, respectively. The EGFR exon 19 del was 60.1% and L858R was 39.9%. The 3-year DFS rate for each stage was 95%, 78%, 58%, 50%, and 32%, respectively. Among 278 patients, baseline ctDNA was detected in 67 (24.1%) patients: 23.4% (stage IA), 17.6% (IB), 17.9% (IIA), 50.0% (IIB), and 42.3% (IIIA) (P=0.06). In 76.1% (51 of 67) of patients with baseline ctDNA, it was cleared up 4 weeks after surgery. Patients were classified into three groups according to the positivity of ctDNA (Group A: baseline ctDNA negative (n=211), Group B: baseline ctDNA positive, but MRD negative (n=51), Group C: baseline ctDNA positive, but MRD positive (n=16)). The 3-year DFS rate was significantly different among the three groups (83.3% for Group A, 78% for Group B, and 50% for Group C, respectively, P=0.02). After adjusting for clinicopathologic variables, ctDNA group (HR 1.27, 95% CI 1.03-1.57, P=0.03) still remains an independent risk factor regardless stage for DFS.


These results suggest that patients with baseline ctDNA positive or MRD positive were associated with poor DFS in curative resected stage IA-IIIA EGFR M+ NSCLC. Further detailed results of longitudinal monitoring of ctDNA and clinical recurrence will be presented.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.